The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

This subcutaneous CD19/CD3-directed bispecific-TCE (BiTE) demonstrated deep B-cell depletion and a favourable safety profile with weekly injections in Phase 1 trials for non-Hodgkin’s lymphoma ...

The deal centres around TNB-486, a bispecific CD19 and CD3 T-cell engager in phase 1 testing in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (NHL) who have received two or ...

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check out my recommendation for CGEM.

Cambridge, Massachusetts Saturday, April 19, 2025, 15:00 Hrs [IST] ...

The panels used were (1) Immune Cell Composition (markers: CD45 VioBlue, CD4 VioGreen, CD3 FITC, CD56 PE, CD16 PE, 7AAD, CD19 PE-Vio770, CD14 APC, and CD8 APC-Vio770 from Miltenyi Biotec, Bergisch ...